超声分子成像前沿:新型靶向超声造影剂BR55研究进展OA

BR55 is a lipid microbubble ultrasound molecular contrast agent targeting vascular endothelial growth factor receptor 2(VEGFR2).As a targeted ultrasound contrast agent that has entered clinical evaluation,BR55 marks the transition of ultrasound imaging from the anatomical and functional era into the molecular era.However,despite existing review articles discussing the preclinical research and preliminary clinical application of BR55,there is currently a lack of a detailed review focusing on the various stages of BR55 clinical trials,which limits the comprehensive planning and understanding of the clinical application path of BR55 technology.The latest advancements of this review are reflected in the systematic synthesis and summary of data from completed and ongoing clinical trials of BR55 across all phases,its imaging efficacy across various tumor types,and its potential as a therapeutic response biomarker.This review aims to provide cutting-edge references for domestic scholars and play a core role of ultrasound molecular imaging technology in precision medicine.